Navigation Links
IDM Pharma Announces UVIDEM(R) and EP-2101 Data Presentations at,2007 ASCO Annual Meeting

es not support marketing approval, whether regulatory authorities will approve JUNOVAN within the time frame expected by the Company or at all, and whether the Company will be able to manufacture JUNOVAN even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or any of its collaborators will be able to develop pharmaceutical products using the technologies of the Company, whether clinical trial results to date are predictive of results of any future clinical trials, risks associated with completing clinical trials of product candidates, risks involved in the regulatory approval process for the Company's product candidates, the possibility that clinical testing may reveal undesirable and unintended side effects or other characteristics that may prevent or limit the commercial use of proposed products; whether the cash resources of the Company will be sufficient to fund operations as planned; whether any steps taken by the Company to contain costs will in fact result in sufficient reduction in expenses; reliance on key employees, especially senior management; the risk that the Company may not secure or maintain relationships with collaborators, and the Company's dependence on intellectual property. These factors are more fully discussed in the Company's Annual Report on Form 10-K filed with the SEC for the year ended December 31, 2006 and other periodic reports filed with the SEC. The Company expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.

    CONTACT:

    Bob De Vaere

    IDM Pharma, Inc.

    Chief Financial Officer

    Office: 949-470-6447

CONTACT: Bob De Vaere, Chief Financial Officer of IDM Pharma, Inc.,+1-949-470-6447

Web site: http://www.idm-pharma.com/

Ticker Symbol: (NASDAQ-NMS:IDMI),(NYSE:SNY)

'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Sygnis Pharma AG announces date for presentation of clinical results
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
10. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
11. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
Post Your Comments:
(Date:7/31/2014)... 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... pipeline and new product development efforts. In the second ... Phase 2a study of AZ-002 (Staccato ® ... of patients with acute repetitive seizures.  Additionally, Alexza ... candidates for development - AZ-008 and AZ-009 - ...
(Date:7/31/2014)... 31, 2014  Decision Resources Group,s experts ... by the Affordable Care Act (ACA), which ... pharmaceutical therapies. The ACA altered how Managed ... regulations and expanded access via government-supported programs. ... exchanges—state-based marketplaces set up by states or ...
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, a ... interventional devices to facilitate removal of blood clots, announced ... the financing will support EU commercialization of several approved ... the Lazarus ReCover™ and Lazarus Cover™ in ... reflects investor confidence in the value of our novel, ...
Breaking Medicine Technology:Alexza Provides Pipeline Update 2Alexza Provides Pipeline Update 3Alexza Provides Pipeline Update 4Alexza Provides Pipeline Update 5Alexza Provides Pipeline Update 6Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 2Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 3Health Exchanges Drive Change In MCO Strategies And Physician Prescribing Decisions; Impact On Pharma Mixed 4Lazarus Effect Closes $5 Million Financing 2
(Date:7/31/2014)... PHILADELPHIA Women who recently used birth control pills ... an increased risk for breast cancer, whereas women using ... in Cancer Research , a journal of the ... that use of contemporary oral contraceptives [birth control pills] ... breast cancer risk relative to never or former oral ...
(Date:7/31/2014)... August 01, 2014 The 2013 ... increasing 0.89 points from 75.07 in 2012. The ... tourism-related sectors and integrates them into an overall ... become increasingly more satisfied with Hong Kong over ... consistently excelling in service performance in Hong Kong ...
(Date:7/31/2014)... In today’s world, a good night’s sleep has become ... apnea (a medical problem where the airway collapses during sleep ... the rest they need to face their daily challenges. ... million people in the United States alone have sleep apnea. ... of those treated, many cannot tolerate their prescribed medical device ...
(Date:7/31/2014)... 0-6 Pack Abs has finally been released by ... Dr. James Vegher. Together they have launched a training ... issues, tone core muscles, improve posture, eliminate achy hips, and ... used to re-train the body in order to properly activate ... Pack Abs review, Shane Michaels, a fitness enthusiast, agrees ...
(Date:7/31/2014)... Conway, SC (PRWEB) July 31, 2014 In ... and increasingly difficult to get. Snoring and sleep apnea (a ... stops) robs people and their bed partners of the rest ... to 45% of the population snores and 20 million people ... only 10% have been diagnosed and treated; and of those ...
Breaking Medicine News(10 mins):Health News:Recent use of some birth control pills may increase breast cancer risk 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 2Health News:PolyU Released Report On 2013 Tourist Satisfaction and Tourism Service Quality Indices to Boost Tourism Development 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 2Health News:Zero To Six Pack Abs System Review Exposes Tyler Bramlett And Dr. James Veghers’ New Ab Training Program 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... 2007 Wearing a portable instrument to monitor ... related health consequences may be on the horizon ... University of Houston and The Methodist Hospital. ... the High-Temperature Superconducting Device Applications and Nano-Biophysics Laboratory ...
... DUBLIN, Calif., Oct. 22 SuperGen Inc.,(Nasdaq: ... discovery, rapid,development and commercialization of therapies for solid ... release its 2007,third quarter financial results on Monday, ... the Company,s 2007 third quarter,financial results, and any ...
... American National,Insurance Company (Nasdaq: ANAT ) announced ... diluted share) compared to $54,802,000 ($2.06 per,diluted share) ... tax operating earnings for the third quarter were ... per diluted,share) for the same period in 2006, ...
... 22, 2007 The Journal of the American ... journals today in publishing a global theme issue ... effort among the worlds biomedical publications., The Council ... which involves simultaneous publication by science journals throughout ...
... NY, October 22, 2007 Human Resources for Treating HIV/AIDS: ... Patient Care and STDs has been selected to be ... Launch of the Council of Science Editors Global Theme ... issue is a special worldwide publishing event on October ...
... With health,facilities across the country struggling to make ... (VA) are demonstrating leadership by,collaborating in efforts to ... healthcare supply chain. Through the innovative joint,incentive funding, ... their ongoing,initiatives to both standardize and synchronize product ...
Cached Medicine News:Health News:Fighting obesity may be as easy as ATP, says UH researcher 2Health News:Fighting obesity may be as easy as ATP, says UH researcher 3Health News:SuperGen to Announce 2007 Third Quarter Financial Results October 29, 2007 2Health News:American National Announces Third Quarter 2007 Results 2Health News:American National Announces Third Quarter 2007 Results 3Health News:American National Announces Third Quarter 2007 Results 4Health News:Journal of the American Dental Association spotlights poverty 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 2Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 3Health News:DoD and VA to Reduce Healthcare Supply Chain Costs 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: